Neuromyelitis Optica Spectrum Disorder research hub

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

This study is looking at a new medicine called Satralizumab for children aged 2-11 with a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). It will primarily check how the medicine moves through the body, with a broad look at how well it works and if it's safe.